Improvement Over the Years of Long-Term Survival in High-Risk Lymphoma Patients Treated with Hematopoietic Stem Cell Transplantation as Consolidation or Salvage Therapy

• Published in: Transplantation proceedings Vol. 45; no. 10; pp. 3665 - 3667
• Main Authors: Calderón-Cabrera, C, Márquez-Malaver, F.J, de la Cruz-Vicente, F, Falantes, F, Carrillo, E, Parody, R, Montero, I, González Campos, J, Martino, M.L, Carmona, M, Pérez-Simón, J.A, Espigado, I
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2013
• Subjects: Adolescent; Adult; Child; Communicable Diseases - etiology; Communicable Diseases - mortality; Female; Hematopoietic Stem Cell Transplantation - adverse effects; Hematopoietic Stem Cell Transplantation - mortality; Humans; Kaplan-Meier Estimate; Lymphoma - mortality; Lymphoma - surgery; Male; Middle Aged; Proportional Hazards Models; Recurrence; Risk Factors; Salvage Therapy; Surgery; Tertiary Care Centers; Time Factors; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Young Adult
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2013.11.007

Abstract The role of hemopoietic stem cell transplantation (HSCT) is not well established in certain types of lymphoma, such as those with a high relapse risk or relapsing after initial therapy. New chemotherapeutic schemes and immunotherapy have improved survival of these patients. Nevertheless, there is not enough evidence regarding whether transplantation is the best therapeutic approach. Moreover, published data on long-term follow-up of high-risk lymphoma patients treated with HSCT are scarce. We analyzed 177 consecutive patients diagnosed with a high risk of relapse or with relapsed lymphoma who underwent HSCT after induction with standard chemotherapy in a tertiary academic center from 1989 to 2013. The median age was 40 years. Diagnoses were Hodgkin disease ( n  = 56), diffuse large B-cell lymphoma ( n  = 44), follicular lymphoma ( n  = 29), mantle cell lymphoma ( n  = 15), T-cell lymphoma ( n  = 18), and others ( n  = 15). Patients received either an autologous graft ( n  = 154) in first complete remission (1CR; n  = 59) or more advanced stages (AS; n  = 95), or an allogeneic graft ( n  = 23) in 1CR ( n  = 4) or AS ( n  = 19). In the autologous group, overall survival (OS) at 5 years was 57% and 75% in the periods 1989–2001 and 2002–2013, respectively ( P  = .05). Patients receiving an allogeneic graft presented an OS of 25% and 43% in the 2 periods. With a mean follow-up of 5 years (95% confidence interval 3.5–6.6), for patients receiving a transplant in 1CR, OS at 5 years was 80%, and for those receiving a transplant in AS it was 59% ( P  = .003). Nonrelapse mortality (NRM) at 5 years was 3.1% in the autologous group and 27.9% in the allogeneic group ( P  < .001). The main cause of NRM was infection (44%) in the whole cohort. All this leads to the conclusion that transplantation, as a therapeutic strategy, has shown a high long-term OS in this subgroup of patients with such a poor prognosis. OS improved over the years and reaching 1CR was a good prognostic feature. Infections were the main cause of NRM.